Juno CEO and Co-founder steps down in wake of Celgene acquisition

pharmafile | April 27, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Juno, appointment, pharma 

Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown it more than 500 employees, is to step down from his role now that his company has been acquired by Celgene in a $9 billion deal earlier this year, it has emerged.

Bishop has worked in the industry for more than three decades. Prior to his founding of Juno, he served in a range of executive roles, most recently as Executive in Residence at global private equity firm Warburg Pincus, a company with “significant investment experience” in the pharmaceutical and healthcare industries.

Before this, he acted as Executive Vice President and Chief Operating Officer at Dendreon, a Seattle-based biotech focusing on cancer immunotherapy treatment, and as President of Specialty Medicine at Bayer Healthcare, Senior Vice President of Global Commercial Operations at Chiron Corporation, and Vice President and General Manager of European Biopharmaceuticals.

Neither Bioshop nor Celgene have made any formal announcement on the departure. Just a week previously, the company revealed that it had elected Bishop to its Board of Directors. Mark J Alles, Chairman and Chief Executive Officer of Celgene commented on the decision: “The changes announced today strengthen corporate governance by refreshing our Board of Directors and improving strategic insight provided to management in areas critical to our future success.” […] “Hans is a pioneer in the field of cellular immunotherapy whose expertise will help Celgene lead in this extremely promising area of science.”

Juno’s Executive Vice President of Technical Operations Ann Lee will take over Celgene’s Seattle office, as well as Juno operations in the Seattle area.

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content